Back to top

Buy Rating Affirmed for Regeneron on Eylea HD Success and Innovative Obesity Program

Leerink Partners analyst David Risinger has maintained their bullish stance on REGN stock, giving a Buy rating on March 14. David Risinger has give...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Regeneron Pharmaceuticals, Inc. (REGN)